Three (3) BREAKING studies: i) Viral load of SARS-CoV-2 Omicron BA.5 is lower than that of BA.2 despite the higher infectivity of BA.5 ii)Vitamin D deficiency and SARS-CoV-2 infection D-COVID iii)
by Paul Alexander
Intranasal virus-particle mimicking vaccine enhances SARS-CoV-2 clearance in the Syrian hamster model (Anguita, Patel, Takatsuki)
See the book cover of my book being released November 15th, 2022.
Order via this LINK
This is the BLUE-PRINT for a Republican congress and senate to hold the proper investigations to get to the bottom of the manufacture (Gain-of-Function) and release of COVID-19, as well as investigations of all of the COVID lockdown polices, mandates, and the decisions and actions taken in developing and bringing the COVID gene injection (vaccine). This is imperative for any administration to get accountability for all of the policies and decisions made with regards to COVID-19:
You can pre-order (order) here by clicking on this link:
Order via this LINK
These three studies reinforce what we have been saying all along on each topic and adds to the existing body of evidence.
“Contrary to expectations, the copy numbers of the BA.5 cases (median 4.7 X 104 copies/uL, n = 290) were significantly (p = 0.001) lower than those of BA.2 cases (median 1.1 X 105 copies/uL, n = 184). There was no significant difference between the BA.5 and BA.1 cases (median, 3.1 X 104 copies/uL; n = 215). The results presented here suggest that the increased infectivity of BA.5 is not caused by higher viral loads, but presumably by other factors such as increased affinity to human cell receptors or immune escape due to its L452R mutation.”
“Regarding clinical course, a higher number of subjects with COVID-19 and vitamin D deficiency required hospitalitation OR 2.41 [95%CI 2.22-2-61], intensive unit care (ICU) OR 2.22 [95% CI 1.64-3.02], had a longer mean hospital stay 3.94 (2.29) p=0.02 and higher mortality OR 1.82 [95%CI 1.66-2.01].) Conclusion: Low serum 25 (OH) Vitamin-D level was significantly associated with a worse clinical evolution and prognosis of COVID-19 infection.”
“Performed proof-of-principle pre-clinical vaccine and challenge studies with a virus-particle mimicking intranasal vaccine against SARS-CoV-2. Consistent with the initial study, animals vaccinated with RBD+SpyCage more rapidly cleared SARS-CoV-2 from both the upper and lower respiratory tract, whereas admixtures of SpyCage and RBD, or either component alone did not. These findings demonstrate the intranasal SpyCage vaccine platform can induce protection against SARS-CoV-2 and, with additional modifications to improve immunogenicity, is a versatile and adaptable system for the development of intranasal vaccines targeting respiratory pathogens.”